• View:

Touchpoint Highlights – What ONDC means for Small Businesses

The fourth session in the SKI Touchpoint series was conducted by the Digital Platforms Practice Area, on the theme of Digital Pathways with ONDC for Nano & Small Businesses’. Abhishek Modi, Lead – Digital Platforms at SKI (abhishek.modi@sattva.co.in), moderated this session, featuring Nandita Sharma, the Social Impact Lead for ONDC.

Enabling Gender Equity on the Cotton Farm

This gender sensitisation toolkit seeks to provide an approach for organisations and / or trainers working closely with farming communities or those implementing agricultural programmes.

Navigating Regulatory Rapids of the ESG Landscape

Now, more than ever, the resilience and growth of businesses depend on the proactive actions taken by their leadership to address ESG risks and seize opportunities arising from them. However, a key challenge that they face is understanding and navigating the constantly evolving regulatory landscape. The global business landscape is

Leveraging Digital Health to Accelerate Maternal and Child Health Outcomes

In recent years, India has made considerable progress in its maternal and child health indicators and reduced IMR and MMR by a considerable fraction. Frontline workers like ASHA and ANM have played a central role by improving accessibility, generating awareness and enhancing utilisation of ANC and PNC services.However, there exist

Srikrishna Sridhar Murthy (Krishna)

Srikrishna Sridhar Murthy brings over a decade of work experience working with the leadership team of global foundations, social organisations and corporates to design and scale their social impact initiatives, across India, SE Asia, Africa and Europe. As the CEO at Sattva he is responsible for the overall strategic direction,

How can Technological Solutions Strengthen the Pharmaceutical Supply Chain?

Pharmaceutical production in India has been a formidable force for healthcare, so much so that no written report ever fails to eulogise India as the “pharmacy of the world”. Despite the prowess of Indian pharmaceutical industries in manufacturing affordable generic medicines, poor quality and unavailability of essential drugs, vaccines, and

  • View: